share_log

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen

专注于神经退行性疾病的公司通过威尔伯·罗斯支持的 SPAC 上市，加入阿尔茨海默氏症竞赛 Biogen
Benzinga Real-time News ·  2023/01/18 10:12
  • Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II (NYSE:ROSS), a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million.
  • Wilbur Ross has personally invested $7.5 million through convertible notes and committed up to $12.5 million of capital infusion at the closing.
  • Aprinoia, founded in 2015, is a clinical-stage biotech company developing novel therapeutics and precision diagnostics for treating neurodegenerative diseases.
  • The company has collaborations with Biogen Inc (NASDAQ:BIIB) and Bristol Myers Squibb & Co's (NYSE:BMY) Celgene, which includes certain non-exclusive license agreements on its lead tau PET tracer, APN-1607.
  • "Aprinoia's tau approach is potentially complementary to beta-Amyloid-based products like Lecanemab. We're encouraged by the progress made in this field over the last two years and believe we're partnering with APRINOIA at the right time to continue advancing this field," added Wilbur Ross, CEO of ROSS.
  • Recently, Biogen's second Alzheimer's disease treatment, Leqembi (lecanemab), scored FDA approval in patients with mild cognitive impairment or mild dementia stage of the disease.
  • Concurrently, Aprinoia has out-licensed the China rights of APN-1607 to a large pharmaceutical company, whereby such company licensee has executed a binding term sheet agreeing to lead the product through its current Phase 3 trial in AD and target 2024 for commercialization of APN-1607 in China.
  • The licensee has committed approximately $8 million and RMB 14 million as an upfront payment, milestone payments, and royalties.
  • Aprinoia will continue to lead the development of APN-1607 in other jurisdictions.
  • APN-1607 is in a Phase 2 trial for Alzheimer's Disease and is preparing for a Phase 3 trial in Progressive Supranuclear Palsy in the U.S.
  • Price Action: ROSS shares are up 0.10% at $10.16 on the last check Wednesday.
  • 以神经退行性疾病为重点 阿普里诺亚疗法 已宣布与之进行业务合并 罗斯收购公司二期 （纽约证券交易所代码：ROSS），一家由前商务部长创立的特殊用途收购公司 威尔伯·罗斯，股权价值为2.8亿美元。
  • 威尔伯·罗斯通过可转换票据亲自投资了750万美元，并在收盘时承诺注入高达1,250万美元的资金。
  • Aprinoia成立于2015年，是一家临床阶段的生物技术公司，开发治疗神经退行性疾病的新疗法和精准诊断。
  • 该公司与以下机构合作 百健公司 （纳斯达克股票代码：BIIB）和 Bristol Myers Squibb's （纽约证券交易所：BMY） Celgene，其中包括其 lead tau PET 示踪剂 APN-1607 的某些非排他性许可协议。
  • “Aprinoia的tau方法有可能补充Lecanemab等基于β-淀粉样蛋白的产品。ROSS首席执行官威尔伯·罗斯补充说，我们对过去两年在该领域取得的进展感到鼓舞，并相信我们与APRINOIA合作的时机正是时候，以继续推动该领域的发展。
  • 最近，Biogen的第二种阿尔茨海默病治疗药物Leqembi（lecanemab）在患有轻度认知障碍或轻度痴呆阶段的患者中获得了美国食品药品管理局的批准。
  • 同时，Aprinoia 已将 APN-1607 在中国的权利超出给一家大型制药公司，该公司的被许可方签署了一份具有约束力的条款表，同意带领该产品完成目前在公元的第三阶段试验，并定于 2024 年在中国将 APN-1607 商业化。
  • 被许可方已承诺约800万美元和1,400万元人民币作为预付款、里程碑付款和特许权使用费。
  • Aprinoia 将继续引领其他司法管辖区 APN-1607 的发展。
  • APN-1607 正在进行一项针对阿尔茨海默病的 2 期试验，并正在为在美国进行性核上麻痹的 3 期试验做准备。
  • 价格走势： 周三的最后一张支票中，ROSS股价上涨0.10％，至10.16美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发